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Abstract The wide spectrum of naturally occurring mutations
able to activate the thyrotropin (TSH) receptor provides a useful
tool to approach the structure of the active state(s) of the
glycoprotein hormone receptors. Here we show that the side-
chain of the highly conserved N7.49 (Asn 674) in TM7 is
mandatory for activation of the TSH receptor, not only by
TSH, but also by a panel of eight natural and two artificial
activating mutations. Basal activity levels of the mutants were
significantly decreased by suppression of the side-chain of N7.49
(N7.49A double mutants). In addition, comparative effects of
the N7.49A substitution on the ten mutants demonstrate that
basal activity and agonist- or mutation-stimulated activity might
involve different structural changes. ß 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Glycoprotein hormone receptors (thyroid-stimulating hor-
mone receptor (TSHr), luteinizing hormone/CG receptor (LH/
CGr), follicle-stimulating receptor (FSHr)) constitute a sub-
family of the well-conserved rhodopsin-like G protein-coupled
receptors (GPCRs) [1]. They are characterized by a dual struc-
ture made of a large amino-terminal extracellular domain
(ECD), the high-a⁄nity binding site of the individual hor-
mones [2^5], and a transmembrane region of seven K-helices
(TMs), responsible for signal transduction. Binding of the
hormones to the ECD triggers conformational changes of
the seven TMs leading to an active state of the receptor.
The glycoprotein hormone receptors are mainly coupled to
Gs but, at high concentration of their agonists, they also
couple to Gq [6]. The intramolecular mechanisms by which
binding of the hormones to the ECD activates the transmem-
brane part of the receptors are the subject of active investiga-
tions but remain largely unknown.
In contrast to the LH/CGr and FSHr, the TSHr has been
shown to present signi¢cant basal activity in the absence of
ligand [7,8]. In addition, more than 25 naturally occurring
mutations have been found to increase dramatically TSHr
constitutive activity, leading to acquired diseases such as toxic
adenomas or (rarely) thyroid cancer, and autosomal dominant
forms of hereditary hyperthyroidism [9,10]. Quite unexpect-
edly, these mutations have been located in all places of the
receptor: the ECD, the extracellular and intracellular loops,
or the TM region. Interestingly, such activating mutations are
less frequently found in the LH/CGr and the spectrum of
residues involved seems to be narrower [11]. For the FSHr,
no convincing natural mutant has been identi¢ed and the
receptor is resistant to activation by many amino acid substi-
tutions with a strong activating e¡ect, when present in homol-
ogous segments of the TSH or LH/CG receptors [12].
In a recent study, we showed that a highly conserved Asn in
TM7 (part of the canonical NPXXY signature of rhodopsin-
like GPCRs) was implicated in the activation mechanism of
the TSHr [13]. In the basal state of the receptor this residue
N7.49674 (see Section 2 for description of the numbering sys-
tem) was found to interact with a conserved Asp in TM6
(D6.44633). Breaking of this interaction (e.g. as a consequence
of natural or arti¢cial mutations a¡ecting D6.44633) was pro-
posed to release N7.49, rendering its side-chain available for
interactions implicated in the activation mechanism. In agree-
ment with this view, we showed that the presence of an Asn
(or Asp) residue in position 7.49 was mandatory for activation
of the receptor by TSH. Although it bound TSH with normal
a⁄nity, an N7.49A mutant lost the ability to be stimulated by
TSH. The wide spectrum of mutations capable of activating
the TSHr provides, in theory, a unique opportunity to ap-
proach the structure of the active state(s) of the glycoprotein
hormone receptors. In the present study, as a ¢rst step in this
direction, we demonstrate that the side-chain of N7.49 was
required for activation of the TSHr, not only by TSH, but
also by a panel of eight natural and two arti¢cial activating
mutations.
2. Materials and methods
2.1. Numbering scheme of GPCRs
The standardized numbering system of Ballesteros and Weinstein
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was used throughout to identify residues in the transmembrane
segments of di¡erent receptors [14]. Each residue is identi¢ed by
two numbers: the ¢rst (1 through 7) corresponds to the helix in which
it is located; the second indicates its position relative to the most-
conserved residue in that helix, arbitrarily assigned to 50. For instance
N7.49 is the asparagine in TM7, located one residue before the highly
conserved proline P7.50. Residue D2.50 corresponds to Asp 460 in the
TSHr numbering; S3.36 to Ser 505; E3.49 to Glu 518; V5.58 to
Val 597; T6.43 to Thr 632; D6.44 to Asp 633 and N7.49 to Asn
674. For residues located outside the TMs (S281 in the ECD and
I486 in the ¢rst extracellular loop, Y601 and D6.30 at the border
between TMs and intracellular loops), we used the numbering system
of the TSHr.
2.2. Site-directed mutagenesis of the TSH receptor
Plasmids encoding the various TSHr mutants were constructed by
site-directed mutagenesis using PCR ampli¢cations as described pre-
viously [13]. Ampli¢ed fragments containing the mutations were
cloned after digestion with appropriate restriction enzymes into the
pSVL expression vector (Amersham Pharmacia Biotech, Freiburg,
Germany) containing the wild-type TSHr [15] using standard proce-
dures. All PCR-generated receptor fragments were veri¢ed by se-
quencing before transfection.
2.3. Transfection and assays
COS-7 cells were grown in Dulbecco’s modi¢ed Eagle’s medium
supplemented with fetal bovine serum 10%, sodium pyruvate 1 mM,
penicillin 100 IU/ml, streptomycin 100 Wg/ml and fungizone 2.5 Wg/ml.
Cells were seeded at a density of 350 000 cells/3 cm dish. One day
later, they were transfected (500 ng DNA/dish) by the DEAE^dextran
method followed by a dimethylsulfoxide shock [16]. Two days after
transfection, cells were used for £ow immunocyto£uorometry and
cAMP studies. Duplicate dishes were used for each assay. Each ex-
periment was repeated at least three times. Cells transfected with
pSVL alone were always run as controls.
2.4. Flow immunocyto£uorometry
Experiments were performed as described previously [13]. Brie£y,
cells were detached with PBS^EDTA^EGTA and after centrifugation
and removing of the supernatant, incubated with the BA8 monoclonal
antibody, obtained from genetic immunization with the wild-type
TSH receptor cDNA [17]. The cells were washed once and incubated
with £uorescein-conjugated gamma chain-speci¢c goat anti-mouse
IgG (Sigma, St. Louis, MO, USA). Propidium iodide was used for
detection of damaged cells, which were excluded from the analysis.
Cells were washed once again and resuspended in 250 Wl PBS^BSA
0.1%. The £uorescence of 30 000 cells per tube was assayed by a
FACScan £ow cyto£uorometer (Beckton Dickinson, Erembodegem,
Belgium).
2.5. cAMP determination
Cells were washed with Krebs^Ringer^HEPES bu¡er (KRH isoton-
ic, pH 7.4). After a preincubation in KRH at 37‡C for 30 min, cells
were incubated in the same bu¡er supplemented with Rolipram 25 WM
(a cAMP phosphodiesterase inhibitor, gift from the Laboratory of
J. Logeais, France), in the absence or presence of various bTSH con-
centrations (Sigma, St. Louis, MO, USA). One hour later, the me-
dium was removed and HCl 0.1 M was added to the cells. The cellular
extracts were dried overnight in a vacuum concentrator (Savant) and
intracellular cAMP was determined exactly as described previously
[18]. Basal cAMP was normalized to cell-surface expression for each
of the constructs. To this end, speci¢c cAMP accumulation ( = cAMP
of receptor-transfected cells3cAMP of the pSVL-transfected cells)
is divided by the speci¢c £uorescence activating cell sorting
(FACS) value ( = £uorescence of receptor-transfected cells3£uores-
cence of pSVL-transfected cells), which can be summarized as: speci¢c
basal activity = (cAMP(receptor)3cAMP(pSVL))/(FACS(receptor)3
FACS(pSVL)). The values are then expressed as percentage of spe-
ci¢c basal activity of the wild-type TSHr. The production of
cAMP in response to TSH, within the cells which have e¡ectively
been transfected, was estimated and expressed as ‘fold stimulation’
in the following way: fold stimulation of cAMP accumulation
by TSH = (cAMPTSH(receptor)3[(cAMPTSH(pSVL)U(1-transfec-
tion e⁄ciency)])/(cAMPbasal(receptor)3[(cAMPbasal(pSVL)U(1-trans-
fection e⁄ciency)]).
3. Results and discussion
3.1. A common ‘conformational pathway’ in all activating
mutations of the TSHr
Amongst the numerous naturally occurring mutations that
have been shown to increase the basal activity displayed by
the wild-type TSHr [7,8,10,19], a subset of eight amino acid
substitutions were selected for their diverse locations in the
receptor structure (see Fig. 1): in the ECD (S281L), in the
extracellular loops (I486F), in the TMs (S3.36505R, V5.58597L,
T6.43632A, D6.44633A), or at the border between TMs and
intracellular loops (Y601N, D6.30G). Despite their being
widely dispersed all these natural mutants are known to in-
duce conformational changes leading to increased constitutive
activity [9,16] (see Fig. 2). In addition we constructed two
arti¢cial mutations a¡ecting the Glu residue in position 3.49
immediately upstream of the most-conserved residue in rho-
dopsin-like GPCRs (R3.50 of the E/DRY motif). Information
available from other GPCRs predicts that the E3.49A and
E3.49Q mutants would display increased constitutive activity
[20^22], and this was indeed the case (Fig. 2).
These ten gain-of-function TSHr mutations were used to
explore whether the highly conserved Asn residue in position
7.49 (the N of the NPXXY motif), which we found to be
mandatory for activation of the receptor by TSH [13], was
similarly implicated in the active conformation(s) achieved by
the individual mutants. In previous experiments, we showed
that, in the basal state, Asn 7.49 interacted with D6.44, a
conserved residue in TM6 of the glycoprotein hormone recep-
tors. Disruption of this interaction, by mutation of D6.44 or
secondary to stimulation by TSH, was proposed to release the
side-chain of N7.49, allowing it to engage in interactions in-
volved in stabilizing the active state(s) of the receptor [13]. We
wanted to investigate here the e¡ect of the N7.49A substitu-
tion when it is added on the background of each of the ten
Fig. 1. Schematic representation of the TSHr with indication of the
mutations studied. Mutated residues are shown in white inside black
circles with the names of the mutants indicated. See Section 2 for
description of the numbering system.
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di¡erent activating mutations. Would all the mutants be sim-
ilarly a¡ected by suppression of N7.49 side-chain, or would
some keep their constitutive activity, thus introducing a hier-
archy in the activating interactions in the mutants? We trans-
fected all single and double mutants transiently in COS-7 cells
and measured surface expression of the receptors by FACS
analysis (Fig. 2A). Basal and TSH-stimulated intracellular ac-
cumulations of cAMP (Fig. 2B) were quanti¢ed and the con-
stitutive activity of the individual constructs was estimated by
normalizing basal cAMP values to receptor expression (see
Section 2 and [13]). The normalized basal activity of the var-
ious single mutants ranged between 570% and 5192% of the
constitutive activity of the wild-type TSHr. Addition of the
N7.49A amino acid substitution to individual mutants de-
creased dramatically their constitutive activity in all cases
(Fig. 2C). For example, normalized basal activity of S281L
was reduced from 3695% to 253% of wild-type, activity of
V5.58L was reduced from 5192% to 298% and activity of
D6.30G was reduced from 470% to 127%. Thus, none of
the receptor constructs was immune to inhibition of its con-
stitutive activity by the N7.49A amino acid substitution,
whether harboring a mutation close to the site of interaction
with TSH in the ECD (S281L) or in the region putatively
involved in interaction with the G protein (E3.49, D6.30G).
Fig. 2. N7.49A substitution reduces the basal activity of activating TSHr mutants. A: Level of expression of the receptors in transfected COS
cells. Cell-surface expression of wild-type TSHr and the di¡erent mutants was measured by FACS using the BA8 monoclonal antibody, which
recognizes a conformational epitope in the N-terminal domain of the receptor. Values represent mean cell £uorescence, normalized to the value
obtained for wild-type TSHr. B: Basal and TSH-stimulated cAMP accumulation. cAMP accumulation was measured in COS cells transfected
with each receptor construct as described in Section 2. TSH was added at 10 mU/ml during 1 h of incubation. C: Normalized constitutive ac-
tivity of wild-type and mutant receptors. Basal cAMP accumulation was normalized to the cell-surface expression (see Section 2). This ¢gure
presents the data of one typical experiment out of at least three, performed independently (error bars: S.E.M.).
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Our results indicate that N7.49 must be involved in a network
of interactions shared by the active conformation(s) achieved
in all individual mutants as well as in the wild-type receptor
stimulated by TSH. Of interest, the N7.49 mutation a¡ects
equally the constitutive activity of mutants with a di¡erent
ability to couple to Gs and Gq (e.g. I486F and D6.30G
[23]). The importance of N7.49 in the activation of rhodop-
sin-like GPCRs by their natural agonists has been docu-
mented in many receptor species [24^26]. The present results
indicate that the molecular interaction(s) of this residue are
crucial to stabilizing the active conformation(s) of the TSHr
and cannot be bypassed, even by activating mutations a¡ect-
ing residues very close to the site of interaction with the
G proteins.
3.2. Some N7.49A double mutants lose virtually all basal
activity
As already noted in Govaerts et al. [13], the N7.49A single
mutant, while losing the ability to be stimulated by TSH, kept
a normalized basal activity comparable to the wild-type re-
ceptor (Fig. 2C). Similarly, in seven of the ten mutants
studied, suppression of the side-chain of N7.49 decreased
strongly their normalized constitutive activity, but never to
a level below that of the wild-type TSHr (Fig. 3A,B). Three
mutants in TM3 make exception, E3.49A, E3.49Q and
S3.36R, with a normalized constitutive activity of the double
mutants signi¢cantly lower than that of the wild-type TSHr.
In particular, the S3.36R/N7.49A double mutant which was
relatively well expressed at the cell surface (27.8 þ 4.3% of the
Fig. 3. Comparative e¡ect of N7.49A on the di¡erent TSHr activating mutants. A: Basal and TSH-stimulated cAMP accumulation in trans-
fected COS cells. cAMP accumulation was measured for each receptor as described in Section 2. TSH was added at 10 mU/ml during 1 h of
incubation. B: Normalized constitutive activity of wild-type and mutant receptors. Basal cAMP accumulation was normalized to the cell-surface
expression (see Section 2). C: TSH-induced cAMP production. The results are expressed in fold stimulation above basal for each mutant (see
Section 2). This ¢gure presents the data of one typical experiment out of at least three, performed independently (error bars: S.E.M.).
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wild-type), displayed a basal activity close to zero (compare
the cAMP values achieved in pSVL-transfected cells,
2.28 þ 0.06 pmol/dish, and in S3.36R/N7.49A transfected cells,
3.30 þ 0.06 pmol/dish; Fig. 3). The di¡erential e¡ect of the
N7.49A mutation on the basal activity of the wild-type
TSHr (no e¡ect) and its ability to be stimulated by TSH
(strong inhibition) [13], and the present observation that
some double mutants are silenced below the level of the
wild-type TSHr, while other keep wild-type-like basal activity,
have profound implication for our understanding of the acti-
vation mechanisms. It suggests that basal and agonist- or
mutation-induced activation may be stabilized by di¡erent
molecular interactions. Strikingly, a molecular explanation
must be found for the observation that, when added on a
wild-type background, the S3.36R or E3.49A/Q substitutions
cause increased constitutive activity whereas, when the same
mutations are engineered on an N7.49A background (present-
ing the same basal activity as the wild-type TSHr), the result is
partial or total silencing. The involvement of E/D3.49 in the
activation of rhodopsin-like GPCRs has been widely recog-
nized [20^22,27,28] and residues in the middle of the TM3
helix have been implicated in the recognition of agonists
[29^31]. With the possibility that some of the activating mu-
tations of the TSHr in TM3 (e.g. S3.36R) might trigger local
conformational changes similar to those resulting from the
binding of agonists in receptors to small ligands, the present
observations may lead to a molecular dissection of these
changes.
3.3. N7.49 is a key residue in the activation of the TSHr
In agreement with observations made previously with the
N7.49A single mutant, the double mutants lose their ability to
respond to TSH (Fig. 3C). A particular case is S3.36R/
N7.49A since at 10 mU/ml of TSH this double mutant dis-
played more than 20-fold stimulation of its basal cAMP level,
when all other double mutants remained virtually una¡ected
(Fig. 3).
Concentration-e¡ect curves (Fig. 4A,B) showed that
S3.36R/N7.49A presents a similar EC50 as the wild-type
TSHr or the S3.36 single mutant (0.67 þ 0.32; 0.44 þ 0.10
and 0.74 þ 0.19, respectively). However, the maximal activity
it reaches is low when compared to that of the wild-type
TSHr, being similar to the basal activity of most of the other
double mutants and the wild-type TSHr. For comparison, and
as expected, the N7.49A single mutant was almost insensitive
to TSH (Fig. 3C).
The reason for the exceptional behavior of the S3.36R/
N7.49A double mutant is not clear. One may argue that it
keeps responding to TSH because of its exceptionally low
basal activity. This, in turn, would suggest that the other
N7.49A mutants would actually be kept in a ‘maximally
(though modestly e⁄cient) stimulated state’. According to
this view, it would be the peculiar conformation of S3.36R/
N7.49A (see discussion above) which would be responsible
both for its low basal activity and for allowing it to respond
to the structural changes induced by the agonist. However, a
low basal activity is not enough to allow for stimulation of the
double mutants by TSH; the E3.49A/N7.49A and E3.49Q/
N7.49A double mutants, which display a normalized basal
activity much lower than the wild-type TSHr, have lost the
ability to be stimulated by TSH (Fig. 3).
4. Conclusion
Our experiments identify N7.49 as a key residue in the
activation mechanism of the TSH receptor by its natural ago-
nist and, more importantly, by a series of very diverse activat-
ing mutations, including those a¡ecting the canonical E/DRY
motif. They also demonstrate that basal activity and agonist-
or mutation-stimulated activity might involve di¡erent struc-
tural changes. The challenge is now to identify the partners of
N7.49 as well as the mosaic of interactions stabilizing the
active state(s) of the TSHr. The availability of a particularly
large panel of activating mutations should make this a real-
istic endeavor for the TSHr by a combination of molecular
modeling, functional assays and site-directed mutagenesis.
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Fig. 4. TSH stimulation of the S3.36R/N7.49A mutant. TSH-in-
duced cAMP accumulation in COS cells transfected with the di¡er-
ent mutants. The curves represent a typical experiment out of at
least three, performed independently. Results were analyzed by non-
linear regression using the GraphPad Prism software. A: Absolute
cAMP values are shown in this panel, demonstrating the ability of
TSH to induce signi¢cant response in the mutant S3.36R/N7.49A.
B: Data were normalized between basal and maximum values
(Emax).
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